louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05675267: Interest of the HEART Score for the Management of Patients With Chest Pain in Emergency Department
Official title: Interest of the HEART Score for the Management of Patients With Chest Pain in Emergency Department
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Coronary Syndrome
Keywords: Acute Coronary Syndrome
chest pain
emergency department
HEART score
Lead sponsor: Université de Reims Champagne-Ardenne
Sponsor class: OTHER
First posted: 2023-01-09
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patient with chest pain consulting in emergency department

Brief summary: Chest pain is a frequent reason of consultation in emergency department. Emergency physician have to identify patients at high risk of Acute Coronary Syndrome from those presenting a lower risk.

Detailed description: The aim of the study is to study the interest of the HEART score for the management of patients with chest pain in emergency department

Eligibility criteria: Inclusion Criteria:

men and women Aged more than 18 Chest pain Consulting in emergency department Agreeing to participate to the study

Exclusion Criteria:

aged less than 18 not agreeing to participate to the study

Primary outcomes:
measure: HEART score
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01541267: The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria
Official title: The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria in Chronic Non-diabetic Kidney Disease: a Double-blind Cross-over Randomised Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Chronic Kidney Disease
Proteinuria
Keywords: aliskiren
eplerenon
telmisartan
direct renin inhibitor
ACE inhibitor
mineralocorticoid inhibitor
proteinuria
chronic kidney diseases
renin-angiotensin-aldosterone system
Lead sponsor: Medical University of Gdansk
Sponsor class: OTHER
First posted: 2012-02-29
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The main purpose of the study is to compare the effects of three different types of RAAS blockade on 24 hours proteinuria in patients with non-diabetic chronic kidney disease.

Detailed description: Pharmacological blockade of the renin-angiotensin-aldosterone system (RAAS) is the main target of therapy to reduces both proteinuria and the rate of decline of the glomerular filtration rate in non-diabetic chronic renal diseases. Despite recent progress, however, there is still no optimal therapy that can stop the progression of these nephropathies. Therefore, it is necessary to optimize such treatment for further improving renal outcome.

The aim of the present study was to compare the effects of three different types of RAAS blockade: (1) mineralocorticoid receptor blocker (MRB) + angiotensin receptor antagonist (ARA); (2) direct renin inhibitor (DRI) + ARA and (3) double maximal dose of ARA on 24 hours proteinuria in patients with non-diabetic chronic kidney disease

Eligibility criteria: Inclusion Criteria:

* age 18-65 years
* chronic non-diabetic proteinuric nephropathy
* chronic kidney disease stage 1-3
* stable proteinuria above 500 mg/24 hours
* blood pressure above 125/75 mmHg and below 150/95 mmHg
* no steroids or other immunosuppressive treatment for a minimum of six months before the study

Exclusion Criteria:

* unstable coronary heart disease
* decompensated congestive heart failure in the previous 6 months
* episode of malignant hypertension or stroke in the history
* diabetes
* creatinine clearance below 30 ml/min
* pregnancy

Primary outcomes:
measure: Difference in urinary albumin-to-creatinine ratio (UACR) between treatment arms
timeFrame: baseline and the end of 8 week treatments
Secondary outcomes:
measure: Difference in transforming growth factor beta (TGF-beta) between treatment arms
timeFrame: baseline and the end of 8 week treatments
measure: Difference in serum potassium and creatinine between treatment arms
timeFrame: baseline and the end of 8 week treatments
Other outcomes:
Locations:
Study officials:
affiliation: Departmen of Nephrology, Transplantation adn Internal Medicine, Medical University of Gdańsk, Poland
name: Bolesław Rutkowski, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02912767: Prevalence of Self Reported Lymphedema in Patients With Endometrial Cancer
Official title: Prevalence of Self Reported Lymphedema in Patients With Endometrial Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometrial Cancer
Lymphedema
Keywords: lower-extremity lymphedema
16-1001
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2016-09-23
Enrollment: 625
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be identified from a retrospective database maintained by the GYN DMT. Patients will be contacted by mail for the first attempt at recruitment.

Brief summary: The investigators are interested in understanding how the patient has been doing since their surgery for endometrial cancer and if they are experiencing any symptoms related to lymphedema (swelling) in the your lower body. The investigators hope that information from the patient and others will help them improve care for women treated for endometrial cancer.


Eligibility criteria: Inclusion Criteria:

* Presented to MSK with newly diagnosed endometrial carcinoma of any histologic profile clinically confined to the uterus and/or uterine cervix
* Underwent primary surgery at our institution, to include at least a total hysterectomy via laparotomy, laparoscopy, or robotic approach, between January 2006 and December 2013
* Alive at the time of study activation

Exclusion Criteria:

* Had documented macroscopic evidence of extrauterine disease at the time of initial diagnosis

Primary outcomes:
measure: compare lymphedema prevalence
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Mario Leitao, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00967967: Validation of the Rhinitis Control Scoring System (RCSS)
Official title: Validation of a Rhinitis Control Tool : the Rhinitis Control Scoring System (RCSS)
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: NA
Conditions: Asthma
Rhinitis
Keywords: control
symptoms
Lead sponsor: Laval University
Sponsor class: OTHER
First posted: 2009-08-28
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Many patients suffering from allergic rhinitis do not recognize or perceive their symptoms. Instruments have been developed to assess quality of life in rhinitis, asthma or both, but there is a need to develop validated tools or methods to assess rhinitis control among rhinitis and/or asthmatic patients. The aim of this study is to assess the discriminative and evaluative properties of the RCSS in asthmatic patients with allergic rhinitis.

Detailed description: Allergic asthmatic subjects showing seasonal rhinitis symptoms will be recruited. The discriminative (internal consistency, cross sectional construct validity and reliability) and evaluative (responsiveness and longitudinal construct validity) properties of the RCSS will be evaluated as well as the relationship between rhinitis control and asthma control. RCSS will be completed at various time points during the seasonal allergic period.

Eligibility criteria: Inclusion Criteria:

* asthma
* seasonal allergic rhinitis

Exclusion Criteria:

* smoking
* nasal polyposis

Primary outcomes:
measure: Discriminative (internal consistency, cross sectional construct validity and reliability) and evaluative (responsiveness and longitudinal construct validity) properties of the RCSS.
timeFrame: March to November 2009
Secondary outcomes:
measure: The relationship between rhinitis control and asthma control.
timeFrame: March to November 2009
Other outcomes:
Locations:
city: Québec
country: Canada
facility: Institut universitaire de cardiologie et de pneumologie de Québec
state: Quebec
Study officials:
affiliation: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
name: Louis-Philippe Boulet, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Boulay ME, Boulet LP. The Rhinitis Control Scoring System: Development and validation. Am J Rhinol Allergy. 2016 Jan-Feb;30(1):54-9. doi: 10.2500/ajra.2016.30.4260.
Clinical trial NCT03848767: A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges
Official title: An Early Feasibility Study to Evaluate the Functionality and Safety of an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus During Meal Challenges
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 1 Diabetes Mellitus
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2019-02-21
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes. The purpose of this study is to assess the safety of the AID system during meal challenges.


Eligibility criteria: Inclusion Criteria:

* Participants with T1DM for at least 2 years and who have used an insulin delivery system with any rapid-acting insulin analog for the preceding 6 months
* Have a body mass index of 18.5 to 37 kilogram per meter squared
* Have a hemoglobin A1c level ≥6.0% and ≤9.0%

Exclusion Criteria:

* Have known allergies or history of hypersensitivity to insulin lispro
* Have had an episode of severe hypoglycemia within the past 6 months
* Have had more than 1 episode of diabetic ketoacidosis in the past 6 months

Primary outcomes:
measure: Number of Adverse Events (AEs)
timeFrame: In-Patient Period (3 Days)
measure: Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL
timeFrame: In-Patient Period (3 Days)
Secondary outcomes:
Other outcomes:
Locations:
city: Renton
country: United States
facility: Rainier Clinical Research Center
state: Washington
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT06173167: Clinical Evaluation of Full Contour Zirconia Chairside CAD/CAM Crowns
Official title: Clinical Evaluation of Full Contour Zirconia Chairside CAD/CAM Crowns
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Dental Disorders Hard Tissues of Teeth
Dental Diseases
Keywords: Dental Caries, Caries
Lead sponsor: Ivoclar Vivadent AG
Sponsor class: INDUSTRY
Collaborators: name: University of Michigan
First posted: 2023-12-15
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This investigation will be a randomized, prospective, longitudinal clinical trial to study the clinical performance of a new monolithic, zirconia material with shade, translucency and material graduation for chairside CAD/CAM crowns. The restorations will be luted either with a self-adhesive luting material or a conventional cement. The crowns will be evaluated for a period of two years.


Eligibility criteria: Inclusion Criteria:

* at least 18 years of age
* at least one carious lesion, defective restoration, or fractured portion of the tooth to be restored on a maxillary or mandibular premolar or molar tooth - Each lesion, fracture, or defective restoration should exhibit sufficient size or loss of tooth structure requiring a full crown restoration.
* tooth should have at least one opposing tooth in occlusion and one adjacent tooth with an intact proximal contact
* No more than ten teeth that are endodontically treated may be included in the study, equally divided between the two groups of crowns. All remaining teeth in the study will test vital and be asymptomatic at the beginning of treatment.
* No more than two restorations will be placed per patient

Exclusion Criteria:

* Sensitive teeth
* Teeth with a history of direct or indirect pulp capping procedures
* Patients with significant untreated dental disease to include periodontitis and/or rampant caries
* Women who self-report that they are possibly pregnant, pregnant, or lactating, as elective dental treatment is not indicated at these times
* Patients with a self-reported history of allergies to the materials to be used in the study including composite resin cements or zirconia restorative materials
* Patients unable to return for the recall appointments

Primary outcomes:
measure: Short-term Post-operative Sensitivity
timeFrame: 4 weeks
Secondary outcomes:
measure: Quality Criteria (modified FDI criteria)
timeFrame: 1 year to 2 years
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan School of Dentistry
state: Michigan
Study officials:
affiliation: University of Michigan
name: Dennis J. Fasbinder, DDS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07022067: EVOLVING AZIMUTH IN MUSA CONTEXT
Official title: EVOLVING AZIMUTH IN MUSA CONTEXT
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Heart Failure
Blood Pressure
Weight Change
Telemonitoring
Lead sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Sponsor class: OTHER
Collaborators: name: ASST Grande Ospedale Metropolitano Niguarda
name: University of Milan
First posted: 2025-06-15
Enrollment: 184
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Non-pharmacological, randomized, nonprofit medical device intervention. The study aims to identify the positive impacts (co-creation), and negative impacts (co-destruction), resulting from the use of telemedicine, and, in particular, the telemonitoring service for patients with heart failure

Detailed description: The patient diagnosed with heart failure is randomized to either the experimental or control arm. The patient in the experimental arm downloads a telemonitoring application where they enter their pressure and body weight data, which is revised by the hospital team via a platform. Patients from both arms complete a questionnaire during enrollment and during two follow-ups (3 months and 6 months) to examine various dimensions.

Eligibility criteria: Inclusion Criteria:

* Have been diagnosed with chronic CS according to the ESC guidelines;
* Over 18 years of age;
* Patients admitted to hospital or with access to first aid within the last year;
* Smartphome that meets the digital requirements (ie Android or iOS able to download and use the application);
* Wi-Fi or 3G coverage at home;
* Ability to give written informed consent.

Exclusion Criteria:

* Severe psychiatric disorder
* Inability to use portable technologies
* Patients unable to use the equipment provided
* Patients who deny consent to study participation

Primary outcomes:
measure: PAM13-I
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Study officials:
affiliation: IRCCS Fondazione Caì Granda Ospedale Maggiore Policlinico
name: Stefano Prof. Carugo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00873067: Benefit of Complex Fractionated Atrial Electrograms Elimination in Atrial Fibrillation Ablation
Official title: Benefit of Complex Fractionated Atrial Electrograms Elimination in Atrial Fibrillation Ablation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Atrial Fibrillation
Catheter Ablation
Keywords: Atrial fibrillation
Complex fractionated electrograms
CFAE
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
Collaborators: name: Fundacio Clinic Barcelona
First posted: 2009-04-01
Enrollment: 142
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate whether performing complex fractionated atrial electrograms ablation improves outcomes in persistent or atrial fibrillation ablation.


Eligibility criteria: Inclusion Criteria:

* Patients with persistent (more than 7 days, or less than 7 days needing pharmacologic or electric cardioversion)
* Presence of atrial fibrillation at the beginning of the procedure

Exclusion Criteria:

* Hypo or hyperthyroidism
* Persistent long-lasting or non-defined duration atrial fibrillation
* Hypertrophic myocardiopathy
* Implantable defibrillation or pacemaker implanted
* Moderate or severe mitral valve disease or mitral prosthetic valve
* Ejection fraction less than 30%
* Left atrial anteroposterior diameter more than 50 mm.
* Previous atrial fibrillation ablation
* Contraindication to anticoagulation
* Left atrium thrombus
* Current infective disease or sepsis
* Pregnant women
* Current unstable angor
* Acute myocardial infarction in last 3 months
* Atrial fibrillation secondary to ionic disturbance, thyroids disease or secondary to any other reversible or non cardiovascular disease
* Reduced expectancy of life (less than 12 months)
* Patient participating in another clinical study that investigates a drug or device
* Psychologically unstable patient or denies to give informed consent
* Any cause that contraindicate ablation procedure or antiarrhythmic drug

Primary outcomes:
measure: Freedom from atrial arrhythmias without antiarrhythmic drugs
timeFrame: 1-year follow-up
Secondary outcomes:
measure: Freedom form atrial arrhythmias with or without antiarrhythmic drugs
timeFrame: 1-year follow-up
measure: Presence of any complications in the acute phase or during follow-up
timeFrame: 1-year follow-up
measure: Freedom from atypical atria flutter
timeFrame: 1-year follow-up
measure: Increase in radioscopy time and radiofrequency application time
timeFrame: 1-year follow-up
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Clinic Universitari de Barcelona
Study officials:
affiliation: Hospital Clinic Universitary de Barcelona
name: Lluís Mont, MD
role: STUDY_CHAIR
affiliation: Hospital Clínic Universitari de Barcelona
name: Elena Arbelo, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04948567: Efficacy of Split-dose of Oral MMS for Bowel Preparation in Elderly Patients
Official title: Efficacy of Split-dose of Oral Magnesium Sulfate Solution for Bowel Preparation in Elderly Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colonic Adenoma
Bowel Preparation
Keywords: bowel preparation
Oral magnesium sulfate solution
polyethylene glycol solution
Lead sponsor: Air Force Military Medical University, China
Sponsor class: OTHER
First posted: 2021-07-02
Enrollment: 1174
Sex: ALL
Minimum age (years): 60
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Adequate bowel preparation is critical for successful colonoscopy and a large volume of PEG was required for bowel preparation in patients undergoing colonoscopy. The investigators conducted a a prospective, randomized, controlled study to compare low dose of oral magnesium sulfate solution with high dose PEG. The investigators found that patients who took low dose of oral magnesium sulfate solution had similar bowel preparation quality to patients who took PEG,but accompanied with fewer adverse events and better tolerance.


Eligibility criteria: Inclusion Criteria:

* patients who underwent colonoscopy

Exclusion Criteria:

* known or suspected bowel stricture or obstruction;
* history of colorectal surgery;
* significant gastroparesis or gastric outlet obstruction;
* toxic colitis or megacolon;
* severe acute inflammatory bowel disease;
* active gastrointestinal bleeding;
* suspected or confirmed chronic renal insufficiency and heart illness;
* disturbance of electrolytes ;
* unable to provide informed consent

Primary outcomes:
measure: The rate of patients with adequate bowel preparation
timeFrame: 1 year
Secondary outcomes:
measure: The rate of adenoma detection
timeFrame: 1 year
measure: the numbers of patients with adverse events
timeFrame: 1 year
measure: The cecal intubation rate
timeFrame: 1 year
measure: The time of Cecal intubation
timeFrame: during procedure
measure: the time during Withdrawal phage
timeFrame: during procedure
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Endoscopic center, Xijing Hospital of Digestive Diseases
state: Shanxi
city: Beijing
country: China
facility: Department of Gastroenterology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital,
Study officials:
References:
citation: Ge F, Kang X, Wang Z, Zhu H, Liao L, Wang M, Jia J, Lou L, Guo X, Pan Y, Wan J. Low-dose of magnesium sulfate solution was not inferior to standard regime of polyethylene glycol for bowel preparation in elderly patients: a randomized, controlled study. Scand J Gastroenterol. 2023 Jan;58(1):94-100. doi: 10.1080/00365521.2022.2106154. Epub 2022 Aug 3.
Clinical trial NCT05897567: Effect of Ketogenic Diet on Muscle Hypertrophy
Official title: Effects of Ketogenic Diet on Muscle Hypertrophic Response to Resistance Exercise
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy Nutrition
Lead sponsor: University of Padova
Sponsor class: OTHER
First posted: 2023-06-09
Enrollment: 24
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the effects of 4 weeks of carbohydrate deprivation (through a ketogenic diet) on hypertrophy signalling after a single bout of exercise in healthy trained male subjects, and the impact on body composition, muscle strength, and blood parameters.


Eligibility criteria: Inclusion Criteria:

* at least 2 years of resistance-training experience
* Body mass index: more than 18 kg/m2 and less than 30 kg/m2

Exclusion Criteria:

* metabolic diseases or noncommunicable diseases (cardiovascular, liver, respiratory, cancer, etc)
* experience with the ketogenic diet (last six months)
* acute inflammatory status
* treatment with steroids in the past 3 months

Primary outcomes:
measure: mammalian target of rapamycin (mTOR) signalling
timeFrame: Change from baseline to 4 weeks
Secondary outcomes:
measure: Skeletal muscle mass
timeFrame: Change from baseline to 4 weeks
Other outcomes:
Locations:
city: Padua
country: Italy
facility: Nutex LAB
Study officials:
affiliation: University of Padova
name: Antonio Paoli, MD
role: PRINCIPAL_INVESTIGATOR
References: